Carrier Connect Data Solutions' subsidiary PureColo USA signed a five-year agreement for the full 4MW capacity of its new Alpharetta data center, potentially generating CAD $88.9 million in revenue. The deal starts with a 3MW deployment in November 2026, with monthly billings of about USD $1.05 million, expected to grow to 4MW within six months. This marks a major milestone in Carrier's strategy to convert data center infrastructure into long-term recurring revenue, with plans to expand further on a 25MW letter of intent. The Alpharetta facility could generate EBITDA margins of 25-30%, signaling strong future cash flow potential.
Carrier Connect Data Solutions' new Alpharetta data center deal is set to generate CAD $88.9 million over five years, marking a significant expansion. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 19, 2026 16:11 WIB: out of 150 priced US tech stocks, 110 rose and 18 fell today. Notable movers include ASX at USD 41.00 (+3.72%), NBIS at USD 171.47 (+3.63%), and DDOG at USD 255.98 (+3.59%).
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
